<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01559207</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2011/SB-02</org_study_id>
    <secondary_id>2011-A01634-37</secondary_id>
    <nct_id>NCT01559207</nct_id>
  </id_info>
  <brief_title>Reproducibility of Plasma Nucleosomes and Free DNA as Markers for Venous Thromboembolism</brief_title>
  <official_title>Reproducibility of Plasma Nucleosomes and Free DNA as Markers for Venous Thromboembolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate, for 15 healthy volunteers and for 15
      patients with a history of venous thromboembolism (VTE), the monthly variation (over 6
      months) of plasma nucleosome and free DNA concentrations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of this study are:

      A. To describe, for 15 healthy volunteers with no history of venous thromboembolism (VTE),
      plasma nucleosome and DNA concentrations.

      B. To describe, for 100 patients with a history of VTE currently consulting for chronic
      disease or thrombophilia work-up, plasma nucleosome and DNA concentrations.

      C. To compare plasma nucleosome and DNA concentrations between healthy volunteers and VTE
      patients

      D. To describe, for 100 patients with a history of VTE currently consulting for chronic
      disease or thrombophilia work-up, the relationships between classification of VTE and plasma
      nucleosome concentrations:

        -  anatomical classification of VTE: (i)superficial, deep ((ii)distal or (iii)proximal), or
           (iv)pulmonary embolism

        -  circumstantial classification of VTE: (i) triggered, no chronic risk factor; (ii)
           untriggered, with chronic risk factor; (iii)triggered, with chronic risk factor; (iv)
           untriggered, no chronic risk factor (idiopathic)

      E. To describe, for 100 patients with a history of VTE, the variation in plasma nucleosome
      concentrations 6 months after the first evaluation

        -  according to the above anatomical classification

        -  according to the above circumstantial classification

        -  according to intercurrent events and treatments

      F. To compare the plasma concentrations of nucleosomes and free DNA

      G. To evaluate the relationship between plasma nucleosome and free DNA concentrations and:

        -  circulating leukocyte populations: total leukocyte count, absolute number of
           neutrophils, monocytes, lymphocytes

        -  markers of coagulation activation: d-dimers, circulating fibrin monomers

        -  platelet count

        -  patients on antivitamin K: INR, patients receiving heparin: antiXa activity

      H. Creation of a biological collection
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma nucleosome concentration (ng/ml)</measure>
    <time_frame>baseline</time_frame>
    <description>For cohortes T and P</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma nucleosome concentration (ng/ml)</measure>
    <time_frame>6 months</time_frame>
    <description>For cohortes T and P</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma nucleosome concentration (ng/ml)</measure>
    <time_frame>1 month</time_frame>
    <description>For cohortes T and Px</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma nucleosome concentration (ng/ml)</measure>
    <time_frame>2 months</time_frame>
    <description>For cohortes T and Px</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma nucleosome concentration (ng/ml)</measure>
    <time_frame>3 months</time_frame>
    <description>For cohortes T and Px</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma nucleosome concentration (ng/ml)</measure>
    <time_frame>4 months</time_frame>
    <description>For cohortes T and Px</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma nucleosome concentration (ng/ml)</measure>
    <time_frame>5 months</time_frame>
    <description>For cohortes T and Px</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma free DNA concentration (ng/ml)</measure>
    <time_frame>baseline</time_frame>
    <description>For cohortes T and P</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma free DNA concentration (ng/ml)</measure>
    <time_frame>6 months</time_frame>
    <description>For cohortes T and P</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma free DNA concentration (ng/ml)</measure>
    <time_frame>1 month</time_frame>
    <description>For cohortes T and Px</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma free DNA concentration (ng/ml)</measure>
    <time_frame>2 months</time_frame>
    <description>For cohortes T and Px</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma free DNA concentration (ng/ml)</measure>
    <time_frame>3 months</time_frame>
    <description>For cohortes T and Px</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma free DNA concentration (ng/ml)</measure>
    <time_frame>4 months</time_frame>
    <description>For cohortes T and Px</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma free DNA concentration (ng/ml)</measure>
    <time_frame>5 months</time_frame>
    <description>For cohortes T and Px</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemogram</measure>
    <time_frame>baseline</time_frame>
    <description>hemoglobin, platelet count, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemogram</measure>
    <time_frame>6 months</time_frame>
    <description>hemoglobin, platelet count, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemogram</measure>
    <time_frame>1 month</time_frame>
    <description>hemoglobin, platelet count, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemogram</measure>
    <time_frame>2 months</time_frame>
    <description>for cohortes &quot;T&quot; and &quot;Px&quot;: hemoglobin, platelet count, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemogram</measure>
    <time_frame>3 months</time_frame>
    <description>for cohortes &quot;T&quot; and &quot;Px&quot;: hemoglobin, platelet count, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemogram</measure>
    <time_frame>4 months</time_frame>
    <description>for cohortes &quot;T&quot; and &quot;Px&quot;: hemoglobin, platelet count, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemogram</measure>
    <time_frame>5 months</time_frame>
    <description>for cohortes &quot;T&quot; and &quot;Px&quot;: hemoglobin, platelet count, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>1 months</time_frame>
    <description>cohortes &quot;T&quot; and &quot;Px&quot; only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>2 months</time_frame>
    <description>cohortes &quot;T&quot; and &quot;Px&quot; only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>3 months</time_frame>
    <description>cohortes &quot;T&quot; and &quot;Px&quot; only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>4 months</time_frame>
    <description>cohortes &quot;T&quot; and &quot;Px&quot; only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>5 months</time_frame>
    <description>cohortes &quot;T&quot; and &quot;Px&quot; only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>1 month</time_frame>
    <description>cohortes &quot;T&quot; and &quot;Px&quot; only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>2 months</time_frame>
    <description>cohortes &quot;T&quot; and &quot;Px&quot; only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>3 months</time_frame>
    <description>cohortes &quot;T&quot; and &quot;Px&quot; only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>4 months</time_frame>
    <description>cohortes &quot;T&quot; and &quot;Px&quot; only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>5 months</time_frame>
    <description>cohortes &quot;T&quot; and &quot;Px&quot; only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatininemia (µM/L)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatininemia (µM/L)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood Glutamo-oxaloacetate transaminase (UI/L)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood Glutamo-oxaloacetate transaminase (UI/L)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood glutamo-pyruvate transaminase (UI/L)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood glutamo-pyruvate transaminase (UI/L)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood gamma-glutamyl transaminase (UI/L)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood gamma-glutamyl transaminase (UI/L)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C reactive protein (mg/l)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C reactive protein (mg/l)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood fibrinogen (g/l)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood fibrinogen (g/l)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Patients with VTE</arm_group_label>
    <description>Group &quot;P&quot; is composed of all patients with a history of VTE. Group &quot;Px&quot; is a subgroup of 15 patients from group P. Members of &quot;Px&quot; are randomly selected from &quot;P&quot;.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>Group &quot;T&quot;: 15 healthy volunteers with no history of VTE will be included in this group.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EDTA, CTAD and dry tubes; Biological collection at the Nîmes University Hospital.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is composed of 15 healthy volunteers with no history of VTE (group
        &quot;T&quot;) and 100 patients with VTE (group &quot;P&quot;). Fifteen randomly selected members of group P
        make up the sub-group &quot;Px&quot;.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient or volunteer must have given his/her informed and signed consent

          -  The patient or volunteer must be insured or beneficiary of a health insurance plan

          -  The patient or volunteer is available for 6 months of follow-up

        For group &quot;P&quot;:

          -  patient with a history of VTE

        For group &quot;T&quot;:

          -  healthy volunteer

          -  no history of VTE

          -  no history of chronic disease

          -  no history of neoplastic disease

          -  no history of chronic infection

          -  not taking anticoagulants, antiplatelet medications

          -  no acute disease or infection during the last 2 weeks

        Exclusion Criteria:

          -  The patient is participating in another study

          -  The patient is in an exclusion period determined by a previous study

          -  The patient is under judicial protection, under tutorship or curatorship

          -  The patient refuses to sign the consent

          -  It is impossible to correctly inform the patient

          -  The patient is pregnant, parturient, or breastfeeding

          -  The patient gave birth in the past three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie Bouvier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 09</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>March 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2012</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nucleosome</keyword>
  <keyword>plasma nucleosome concentrations</keyword>
  <keyword>free DNA</keyword>
  <keyword>plasma free DNA concentrations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

